Dyadic seeks affordable vaccines and biologics for Africa

Dyadic extends its licensing agreement with Rubic for the use of its C1-cell protein expression platform.

Related Keywords

India ,Julian Naidoo ,Mark Emalfarb ,Dyadic International ,Rubic One Health ,Rubic One ,Upstream Processing ,Markets Amp Regulations ,Biosimilars ,Covid 19 ,Licensing Agreement ,Protein ,Microorganism ,Iologics ,Vaccines ,